Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model ABX464 is the only drug candidate with a potential triple action for COVID-19 treatment: antiviral, anti-inflammatory and tissue repair ****** ABX464, as assessed by RTqPCR, inhibits in vitro viral replication of SARS-CoV-2 (COVID-19) Simultaneously, Abivax receives ANSM and CPP clearance[1] to test ABX464 as promising COVID-19 therapeutic candidate in Phase 2b/3, randomized, 1,034 patient, miR-AGE clinical trial COVID-19 patients die from acute respiratory failure resulting from viral replication inducing pulmonary hyper-inflammation or longer-term fibrosis ABX464 is the sole drug candidate with such promising triple activity, inhibition of SARS-CoV-2 replication shown in vitro, inflammation reduction and tissue repair shown in ulcerative colitis patients ABX464 would meet U.S. NIH/NIAID COVID-19 strategic priorities for novel drugs: antiviral, anti-inflammatory, tissue repair, oral administration, convenient once-daily administration ****** PARIS, France, May 14, 2020 – 06:00 a.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR. ABX464 has already been shown to be an effective drug candidate in a severe inflammatory disease, ulcerative colitis. miR-124 specific upregulation by ABX464 can explain the triple effect of the drug candidate on inhibiting viral replication, down-regulation of cytokines that induce inflammation and tissue repair. The breakthrough scientific data Abivax is reporting today make ABX464 a unique potential treatment for COVID-19 patients. Given the current pandemic and patient’s excessive inflammatory response to viral replication as the primary cause of acute respiratory distress syndrome (ARDS) and death of COVID-19 patients, ABX464 with its convenient oral administration and its potential unique triple mode of action, will be urgently tested in a European clinical trial as a potential new treatment to: - Prevent and reduce inflammation, as already demonstrated in another severe inflammatory disease, ulcerative colitis. Indeed, ABX464 has been shown to upregulate miR-124[2], a “natural brake” of inflammation. miR-124 down-regulates the multiple chemo- and cytokines involved in the COVID-19 cytokine storm, including TNF alpha, IL-1 beta, G-CSF, IL-6, MCP-1 and IL-17. - Reduce viral replication, mediated by RNA quality control and miR-124 induced inhibition of dynamin 2, a key component necessary for viral replication. - Promote tissue repair and decrease pulmonary fibrosis. By binding to the Cap Binding Complex (CBC), ABX464 allows the splicing of a non-coding RNA, LncRNA 205, to produce miR-124, a potent anti-inflammatory microRNA that prevents the translation of multiple chemo- and cytokines as mentioned above. Furthermore, the replication of SARS-CoV-2 requires dynamin 2, a GTPase responsible for vesicle scission and cell penetration of the virus. Dynamin 2 is a target gene of miR-124 and downregulated by miR-124 upregulation. Antiviral experiments were performed at the International Research Center specialized in infectiology at Claude-Bernard-Lyon-1 University, VirPath laboratory. Manuel Rosa-Calatrava, Ph.D., VirPath Co-director at the International Center for Infectiology Research in Lyon, France said: “Although in vitro results cannot predict clinical benefits in patients, this antiviral effect against SARS-CoV-2 with ABX464 obtained in our laboratory is very promising, in addition to the known anti-inflammatory properties. ABX464’s antiviral effect and protection of tissue integrity are significant as they are based on a physiologic in vitro reconstituted human pulmonary epithelium model and not on the more basic monkey kidney Vero E6 cells model”. Philippe Pouletty, M.D., Chairman of Abivax and CEO of Truffle Capital said: “When we patented the anti-SARS-CoV-2 effect of ABX464, based on our research on its mechanism of action and coronavirus physiopathology, we were very cautious about the ability to demonstrate an antiviral effect in such a stringent human pulmonary epithelium model. We wish to thank the VirPath team that was able to do this rapidly and rigorously.” Prof. Hartmut Ehrlich, M.D., CEO of Abivax added: “Our demonstration of the antiviral effect of ABX464 against SARS-CoV-2 further strengthens the rationale for initiating the miR-AGE clinical study, making ABX464 a promising drug candidate to be investigated clinically. With the recent approval of the miR-AGE clinical trial by ANSM (the French regulatory authorities) and the ethics committee, we will soon start patient recruitment to find out whether this triple activity of ABX464 can be translated into clinical benefits for patients diagnosed with COVID-19.” This potential triple role of ABX464 is extremely promising, and it is the only drug candidate in the world today to show such a complementarity. In addition, convenient ABX464 daily oral dosing allows early treatment of patients in or out of hospital, to potentially act on viral replication, cytokine production, pulmonary tissue repair, before severe complications occur. ****** About Abivax Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX. About Truffle Capital Established in 2001, Truffle Capital is an independent European Venture Capital company, specializing in breakthrough technologies in life sciences (BioTech and MedTech) and in FinTech and InsurTech fields. Truffle Capital’s mission is to support the creation and development of young innovative companies able to become tomorrow’s leaders. More information: www.truffle.com – Twitter: @trufflecapital
Pre opening inmiddels op € 22,65
Niemand meer aandeelhouder van Abivax?
Bioteg71 schreef op 14 mei 2020 08:54 :
Niemand meer aandeelhouder van Abivax?
Hier heb je er nog 1! :)) Groet, poil
Eindelijk los ;) En nu richting de 30. Groet, poil
Zodra de 25,95 van eind december wordt gehaald gaan alle remmen los. Kijk eens naar de omzet 200K in nog geen kwartier! Succes, poil
poil-1 schreef op 27 december 2019 13:32 :
Ik kocht ooit een pakket aandelen Galapagos aandelen die ik met winst verkocht heb. Maar ik durf soms niet te kijken of Galapagos al 200 noteert ;)
Dat gaat mij niet nog een keer overkomen. Dit pakket Abivax blijft op de plank.
Groet, poil
Abivax volgens Der Aktionär: Geduld loont “Abivax is ook van plan verschillende antivirale verbindingen te testen tegen Covid-19. Abivax is een van de meest veelbelovende biotech small-caps in Europa. De reset biedt risicobewuste beleggers de mogelijkheid om het Abivax-aandeel toe te voegen aan de langetermijndeposito ', schreef DER AKTIONÄR in nummer 14/2020 en raadde aan om de hete aandelen te kopen tegen prijzen van ongeveer EUR 13,60. Inmiddels omzet 330K Abivax SA 22,70 5,58 32,59 % 10:41:43 Succes en blijf ze vasthouden. Amerika komt nog, poil
www.4investors.de/nachrichten/mobile/... Bijna 45 procent plus is momenteel voor het Abivax-aandeel in Tradegate-handel. Het Franse biotechbedrijf zet de koerssprong vandaag op gang met een bericht over nieuwe wetenschappelijke gegevens over de Covid-19-medicijnkandidaat ABX464, die veel aandacht trekt in de corona-crisis: “Met behulp van RTqPCR (virus-RNA-analyse met behulp van kwantitatieve real-time PCR), werd aangetoond dat ABX464 de in vitro virusreplicatie van SARS-CoV-2 (COVID-19) aantoonbaar remt ”, meldt het bedrijf. ABX464 wordt ontwikkeld voor de behandeling van ernstige ontstekingsziekten zoals colitis ulcerosa. In de huidige fase van de tests moet u echter nog steeds voorzichtig zijn en kunnen de resultaten niet noodzakelijkerwijs worden overgedragen op mensen. "Hoewel in vitro resultaten het klinische voordeel voor patiënten niet kunnen voorspellen, is de antivirale activiteit van ABX464 tegen SARS-CoV-2 die we in ons laboratorium zagen, samen met de bekende ontstekingsremmende eigenschappen van de stof, veelbelovend," zegt Manuel Rosa-Calatrava, mededirecteur van VirPath bij het Centre International de Recherche en Infectiologie (CIRI) in Lyon. "Het antivirale en weefselbeschermende effect van ABX464 is significant omdat het gebaseerd is op een fysiologisch, gereconstitueerd menselijk longepitheelcelmodel en niet op het vereenvoudigde Vero-E6-niercelmodel van apen", zegt Rosa-Calatrava. Abivax werkt nu aan het bevestigen van de gegevens in klinische onderzoeken. Het biotechbedrijf heeft nu goedkeuring gekregen van zowel het Franse Geneesmiddelen Bureau (ANSM) als de ethische commissie voor een fase 2b / 3 klinische proef met ABX464 voor de behandeling van Covid-19-patiënten. Abivax is van plan 1.034 patiënten in te schrijven voor de klinische proef. "Omdat de pathogenese van COVID-19 complex is, moeten we voorzichtig zijn met het mogelijke succes van de miR-AGE-studie", zegt Philippe Pouletty, Abivax-voorzitter en CEO van Truffle Capital. "We hebben voldoende ABX464-capsules op voorraad om ongeveer 50.000 patiënten te behandelen en kunnen binnen enkele maanden ABX464 produceren voor meer dan een miljoen patiënten", zegt Hartmut Ehrlich, CEO van het bedrijf. Abivax: aandeelhouderswaarde wordt "een essentieel criterium" voor de Evotec-partner Met ABX464 heeft de Franse Evotec-partner Abivax een zeer interessant actief ingrediënt tegen ontstekingsziekten zoals colitis ulcerosa in zijn portfolio. Ondanks sterke prijsstijgingen zien analisten nog steeds een hoog prijspotentieel voor het biotechaandeel. Ondertussen staat het bedrijf voor belangrijke vervolgstappen. Groet, poil
Abivax verdient veel meer aandacht. Ik durf wel te stellen dat het bedrijf enorm is ondergewaardeerd. Molecuul ABX464 is breed inzetbaar met prima resultaten tot dusver. Als analisten en grote investeerders dit gaan inzien spuit de koers omhoog. Er staan nog geen 13 miljoen aandelen uit.
Ze (we) hadden pech dat dit prachtig hoopgevend nieuws op een bloedrode beursdag uitkwam. Ik ben wat teleurgesteld door het koersverloop. Maar de Fransen zijn nog geterroriseerd na het genfit debacle van eergisteren, en kiezen momenteel liever eieren voor hun geld. Ja Abivax heeft een enorm potentieel. Onno, je zocht toch een leuke overnamekandidaat ?
€36 million non-dilutive funding from Bpifrance for ABIVAX’ ABX464 Covid-19 program ****** Funding covers 1,034-patient placebo-controlled ABX464 Phase 2b/3 COVID-19 miR-AGE trial, manufacturing scale-up and additional development costs related to the potential filing of ABX464 Marketing Authorization Applications ABX464’s triple effect well suited for COVID-19 treatment evaluation in clinical trial: antiviral, anti-inflammatory and tissue repair ABX464 miR-AGE Phase 2b/3 trial was approved by ANSM and Ethical Committee CPP and is expected to enroll first patients soon Additional European regulatory approvals in process ****** PARIS, France, May 15, 2020 – 10:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that Bpifrance (Copil, SGPI) approved a €36 million non-dilutive funding (€20.1. million grant, and €15.9 million loan refundable upon success) for its Phase 2b/3 trial of ABX464 in high-risk patients with COVID-19 as well as manufacturing scale-up and additional clinical and other development costs. Philippe Pouletty, M.D., Founder and Chairman of the Board of Abivax and CEO of Truffle Capital, said: “We are very pleased to announce this approval of a €36 million non-dilutive funding for the COVID-19 miR-AGE Phase 2b/3 study and ABX464 pharmaceutical and clinical development program, to potentially provide a novel treatment option for patients with COVID-19. We would like to thank Bpifrance, the Secrétariat Général pour l’Investissement and their outstanding teams that worked hard with Abivax to speed-up their in-depth evaluation and decision process. Our gratitude also goes to ANSM, the ethics committee, clinicians and our partners that joined in this special effort. Our goal is to now implement the 1,034 patients ABX464 miR-AGE trial as rapidly as possible and, if we get positive results, bring with no delay ABX464 to the market and manufacture sufficient drug product for patients.” Prof. Hartmut Ehrlich, M.D., CEO of Abivax, said: “The orally available ABX464, with its unique mechanism of action resulting in a triple effect - antiviral, anti-inflammatory, tissue repair - may have the potential to improve the outcome for patients with COVID-19. Now, with funding for the clinical and development program in place, we are rapidly initiating this rigorously designed clinical trial to hopefully translate the promising features of ABX464 into tangible clinical benefits for the patients. If miR-AGE is successful, we will work with regulators to make ABX464 available as quickly as possible, including rapid manufacturing scale-up. In parallel, we continue the ABX464 Phase 2b trial for ulcerative colitis, Phase 2a for rheumatoid arthritis, and the preparation of a Phase 2b trial for Crohn’s disease. Securing this financing from Bpifrance is a first major step towards funding Abivax for the next 18-24 months, preferably non-dilutive.” Bpifrance is the investment bank of the French state, supporting entrepreneurial activities that are in the public interest. The financing will allow to fund the consortium led by Abivax (including Nice University Hospital) in order to conduct the ABX464 COVID-19 miR-AGE clinical study, as well as ABX464 manufacturing scale-up and additional clinical and other development costs. The provision of funding is planned to take place over a period of one year, including expenditures since February 1, 2020, to be implemented as soon as the administrative steps have been completed. The funding consists of €20.1 million in grants and €15.9 million in refundable loans, which Abivax would repay after ABX464 reaches commercial stage. Specific agreements with regards to this financing will be finalized between Abivax and Bpifrance in the coming weeks. Abivax recently announced clearance by the French regulatory authorities (ANSM) and the ethics committee to conduct the randomized, double-blind and placebo-controlled miR-AGE trial in 1,034 elderly or high-risk COVID-19 patients. About 50 French and European clinical study sites are expected to investigate the clinical benefits of Abivax’ lead development candidate ABX464. ABX464 is a small molecule with a unique mechanism of action, upregulating a microRNA, miR-124, with antiviral, anti-inflammatory and tissue repair properties, and with convenient once-daily oral dosing. With its triple effect, the molecule is uniquely positioned to potentially limit replication of SARS-CoV-2 virus, prevent and treat the cytokine storm, hyper-inflammation, and acute respiratory failure syndrome as well as potentially limit long-term lung injury. ABX464 is the only molecule known to have this triple effect. However, given the complexity and rapid development of COVID-19 disease, there is no certainty that any medical benefit can be shown in the miR-AGE trial. The oral dosage form of ABX464 enables the inclusion of hospitalized and, importantly, non-hospitalized COVID-19 patients into the clinical trial, and high-risk patients will be treated early following diagnosis. The design of the miR-AGE trial should ensure the generation of scientifically and medically valid conclusions. Provided patient recruitment can be achieved and the trial is successful, MAA (market authorization application) filings will be done in France, Europe and globally. ****** About Abivax Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX.
hier zijn we toch vertrokken, ..... Ze hebben hun financiering vast !!!!! Okay, liever had ik een partner gezien, maar wat nog niet is kan nog komen. Ze hebben gisteren een OPA (aankoopaanbieding) geweigerd, een bod dat interessant was voor de aandeelhouders (dixit Philippe Pouletty). Ze willen het onderzoek van de Covid19 liever zelf doen. Momenteel hebben ze een voorraad voor 50.000 behandelingen. Met hun industriele partners hebben ze de capaciteit om 1 million dossissen binnen de 6 maanden te maken. Aan een faire prijs van 1.000€ per patient, reken maar .... ALS, INDIEN, de molecule ABX464 doeltreffend zou zijn voor Covid19, dan gaan we naar 100€.... Ondertussen, met al dat goed nieuws, zou 30€ volgende week haalbaar zijn.
grounds for hope ? schreef op 16 mei 2020 17:54 :
hier zijn we toch vertrokken, .....
Ze hebben gisteren een OPA (aankoopaanbieding)
geweigerd, een bod dat interessant was voor de aandeelhouders (dixit Philippe Pouletty).
Hoi Grounds for hope. Hoe kom je aan die info, of stond dat ergens? Dit is een financiering alleen voor COVID-19. Voor financiering andere indicaties krijgen we tzt nog info. Partnering dus ?
Er is een zeer mooi artikel in le magazine Figaro in Frankrijk. in bijlage.
Je kan ook zeer veel info vinden op Twitter. Je zoekt naar Abivax, vooral de recente nieuwtjes...
Ziet er goed uit. DUS vasthouden. Groet, poil
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
870,27
-0,43%
EUR/USD
1,0718
+0,19%
FTSE 100
8.078,86
+0,48%
Germany40^
17.882,10
-1,14%
Gold spot
2.328,86
+0,55%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers